Christine Garabedian knew, for more than two years, what she wanted to do. She described her experience in physicians' offices: "I'd see the reps talking to doctors and I thought, 'That's what I want to do - how come no one lets me do this?' I knew I'd be good at it."
Christine Garabedian knew, for more than two years, what she wanted to do. She described her experience in physicians' offices: "I'd see the reps talking to doctors and I thought, 'That's what I want to do - how come no one lets me do this?' I knew I'd be good at it."
She was right. Now a highly successful representative, Garabedian is celebrating her seven-year anniversary with Knoll this month - and she looks back on her winding road to pharmaceuticals sales wistfully. She studied classical piano, accounting and finally finance in college. With a plan to see the world, she worked as an aide on Capitol Hill, then moved to Tokyo to teach English. When she returned to the States, she knew she wanted to be "out and about," not tied to a desk, and she began to interview with pharmaceutical companies. But with 1991's tight market, Garabedian was passed over for one frustrating reason: "I had no sales experience," she said. Out of the blue, a past contact called about an open position, remembering Garabedian's enthusiasm from a ride-along. "I didn't seek Knoll," Garabedian explained, "I got lucky."
Her "ability to talk to anybody - at all levels," has been one of Garabedian's strengths in the field. She's also developed creative trademarks that range from speaking Japanese in her Japanese-American physician offices to decking herself out in leopard-print accessories (matching the sales aids of one of her products) to handing out California raisins (her father is a raisin producer). Garabedian admitted: "I've got a few different things that make me stand out from other reps."
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.